TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21324825
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin glulisine 2 times daily
Study: 21324825
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin glulisine 1 time daily
Study: 21324825
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin glulisine 1 or 2 times daily
Study: 19147693
Drug: Placebo (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (initial 12 weeks) followed by open active treatment as clinically indicated
Study: 19147693
Drug: Active treatments
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatments (fluoxetine, CBT, combination treatment)
Study: 17468868
Drug: Fondaparinux 2.5
Normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux 2.5 mg
Study: 9496329
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of recombinant human LH and FSH
Study: 8110566
Drug: Group B10
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B10 (10 micrograms kg‐1 bolus dose)
Study: 8110566
Drug: Group B20
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B20 (20 micrograms kg‐1 bolus dose)
Study: 3349887
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (6 g daily)
Study: 3349887
Drug: Aluminum hydroxide
Normalized name: Aluminum Hydroxide
DrugBank: Aluminum hydroxide (DB06723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum hydroxide (7.2 g daily)
Study: 28993394
Drug: Shape‐Up following
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shape‐Up following cancer treatment programme (12 hours over 8 weeks)
Study: 25256304
Drug: General practitioners'
Approvals — FDA: no, EMA: no, PMDA: no
Description: General practitioners' use of argumentation to support treatment advice
Study: 19898884
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training (breathing and aerobic exercises) for 1.5 h, 3 days weekly for 12 weeks
Study: 16611272
Drug: rifaximin 800
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rifaximin 800 mg b.d.
Study: 16611272
Drug: rifaximin 800
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rifaximin 800 mg o.d. + placebo
Study: 14708688
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg daily lamivudine therapy
Study: 11056097
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (0.625 mg) combined with medroxyprogesterone acetate (2.5 mg) daily
Study: 1507822
Drug: Plasmapheresis (PA)
Normalized name: HAEMO-PAK UNIT FOR PLASMAPHERESIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmapheresis (PA) as a treatment
Study: 6742082
Drug: Timolol maleate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol maleate 0.5% eyedrops (used twice a day)
Study: 6742082
Drug: Indomethacin 25
Normalized name: indomethacin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 25 mg (three times a day, given orally)
Study: 20019606
Drug: n-3 FA
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 FA as a treatment option
Study: 17181846
Drug: Valdecoxib 40
Normalized name: valdecoxib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib 40 mg administered pre- and postoperatively
Study: 17181846
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered pre- and postoperatively
Study: 11772245
Drug: Psychopharmacological agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychopharmacological agents
Study: 11772245
Drug: Alternative therapies
Normalized name: HERBS/ALTERNATIVE THERAPIES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative therapies (homeopathy, acupuncture, special diets, herbal medication, psychological treatments, hypnotherapy)
Study: 7974334
Drug: Weight adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight adjusted dose of Fragmin (100 IU/kg) subcutaneously twice a day for 10 days (group A)
Study: 7974334
Drug: Dosage based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage based on anti factor Xa assay to obtain a target concentration of 0.5 to 1 IU/ml (group B)
Study: 2690622
Drug: Ofloxacin 300
Normalized name: ofloxacin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 300 mg given twice daily
Study: 2690622
Drug: Carbenicillin 764
Normalized name: carbenicillin
DrugBank: Carbenicillin (DB00578)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbenicillin 764 mg given every six hours
Study: 2690622
Drug: Trimethoprim/sulfamethoxazole combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim/sulfamethoxazole combination
Study: 24916134
Drug: Albuterol (A)
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (A)
Study: 24916134
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of magnesium sulfate and albuterol (M + A)
Study: 23454551
Drug: CBT (Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT (Cognitive and Behavioural Therapy) for 6 months
Study: 21300930
Drug: AC→T (sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC→T (sequential doxorubicin and cyclophosphamide followed by docetaxel)
Study: 21300930
Drug: TAC (concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC (concurrent doxorubicin, cyclophosphamide, and docetaxel)
Study: 21300930
Drug: Treatment arm,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment arm, time point, age, and tamoxifen use
Study: 2946604
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (Diane, 2 mg)
Study: 2946604
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (Androcur, 100 mg)
Study: 31169293
Drug: MF59-adjuvanted inactivated
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted inactivated A(H7N9) vaccine
Study: 31169293
Drug: AS03-adjuvanted inactivated
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03-adjuvanted inactivated A(H7N9) vaccine
Study: 9807036
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid 500 mg twice daily
Study: 2509103
Drug: Control (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (conventional therapy without acute catheterization)
Study: 30353600
Drug: Accelerated transition
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated transition from oncological treatment to home-based specialized palliative care (SPC) and dyadic psychological support
Study: 27809351
Drug: Memantine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (20 mg/day) plus sertraline (200 mg/day)
Study: 27809351
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus sertraline (200 mg/day)
Study: 19863279
Drug: Adenosine inhalation
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine inhalation challenge
Study: 7961321
Drug: Methacholine inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methacholine inhalation challenge
Study: 20509997
Drug: Entecavir (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir (0.5 mg once daily for 48 weeks)
Study: 17302253
Drug: Lamivudine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine (100 mg once daily for 48 weeks)
Study: 14966092
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m(2) plus carboplatin AUC6
Study: 14966092
Drug: Paclitaxel 225
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 225 mg/m(2) plus carboplatin AUC6
Study: 9135312
Drug: Intrathecal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal fentanyl 0.5 ml (25 micrograms)
Study: 9135312
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 0.5 ml (control group)
Study: 9135312
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine 0.5% 2 ml
Study: 6784976
Drug: Bromocriptine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine 7.5 mg daily
Study: 28418102
Drug: solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: solifenacin 5 mg
Study: 27607187
Drug: darifenacin 7.5
Normalized name: darifenacin 7.5 MG
DrugBank: Darifenacin (DB00496)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: darifenacin 7.5 mg
Study: 20107867
Drug: Topical anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthesia with 0.5 ml preservative-free 1% intracameral lidocaine (2 drops of proxymethacaine 0.5%)
Study: 20107867
Drug: Subtenon anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subtenon anaesthesia with 4 ml 2% lignocaine
Study: 19441669
Drug: peg‐IFNalpha2a (n=18)
Approvals — FDA: no, EMA: no, PMDA: no
Description: peg‐IFNalpha2a (n=18) or peg‐IFNalpha2b (n=8) plus RBV in standard doses
Study: 16025959
Drug: Modified Sanjiasan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Sanjiasan decoction (MSD), one dosage each day for three months.
Study: 16025959
Drug: Naofukang 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naofukang 0.8 g three times a day for three months (Control).
Study: 1714951
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2 day 1; Bleomycin 15 mg IV day 1, and 16 mg/m2/d CI days 1 to 5; Fluorouracil 650 mg/m2/d CI days 1 to 5 (PBF)
Study: 6172999
Drug: Morphine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (1 mg . kg‐1, iv at 100 micrograms . kg‐1 . min‐1)
Study: 27759463
Drug: Ixekizumab Q2W
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab Q2W (80 mg every two weeks after a 160 mg starting dose)
Study: 27759463
Drug: Ixekizumab Q4W
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab Q4W (80 mg every four weeks after a 160 mg starting dose)
Study: 27759463
Drug: Etanercept (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (50 mg bi-weekly)
Study: 22096031
Drug: High ST2
Normalized name: HIGH DENSITY POLYETHYLENE
Approvals — FDA: no, EMA: no, PMDA: no
Description: High ST2 concentrations (>35 μg/L)
Study: 18815445
Drug: Direct-current cardioversion
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-current cardioversion (DCC) vs Pharmacological treatment
Study: 17206078
Drug: Bravo capsule
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bravo capsule
Study: 15991867
Drug: Intramuscular botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular botulinum toxin A (BTX‐A)
Study: 15991867
Drug: Structured rehabilitation
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured rehabilitation (physiotherapy and occupational therapy three times a week for 6 months)
Study: 8560678
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg daily bicalutamide
Study: 8560678
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg daily bicalutamide
Study: 8560678
Drug: 450 mg
Normalized name: aspirin 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg bicalutamide
Study: 1883258
Drug: High-dose right
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose right unilateral electroconvulsive therapy (378-mC charge)
Study: 1883258
Drug: Bilateral electroconvulsive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral electroconvulsive therapy
Study: 30767156
Drug: Immersive Virtual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immersive Virtual Reality Environment (VRE) with Cognitive Behaviour Therapy (CBT); 1 session introducing CBT techniques and 4 VRE sessions
Study: 30767156
Drug: Immersive Virtual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immersive Virtual Reality Environment (VRE) with Cognitive Behaviour Therapy (CBT)
Study: 26771522
Drug: Perindopril 5
Normalized name: amlodipine-perindopril 5 mg-7 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 5 mg/Amlodipine 5 mg (Per/Amlo group)
Study: 26771522
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg (Amlo group)
Study: 26771522
Drug: Perindopril 4
Normalized name: perindopril 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 4 mg (Per group)
Study: 22785114
Drug: ramipril +
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ramipril + high‐dose rapamycin (trough level 6‐8 ng/mL)
Study: 22785114
Drug: ramipril +
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ramipril + low‐dose rapamycin (trough levels 2‐4 ng/mL)
Study: 20188315
Drug: Nutritional therapy
Normalized name: nutritional therapy for GSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional therapy in combination with exercise training
Study: 11923049
Drug: Prostacyclin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostacyclin plus conventional therapy
Study: 10438381
Drug: Efavirenz, 600
Normalized name: Efavirenz, 600 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz, 600 mg daily
Study: 29989171
Drug: Antioxidant (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant (500 mg l-ascorbic acid and 450 IU dl-α-tocopherol acetate, 2 capsules/day for 8 weeks)
Study: 29989171
Drug: Placebo (cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (cellulose capsules of identical appearance)
Study: 25266929
Drug: 5-week Internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-week Internet-based guided self-help program based on exposure therapy with weekly student support
Study: 17699476
Drug: C.E.R.A. once
Approvals — FDA: no, EMA: no, PMDA: no
Description: C.E.R.A. once monthly
Study: 17699476
Drug: C.E.R.A. twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: C.E.R.A. twice monthly
Study: 15073671
Drug: Full-dose ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Full-dose ganciclovir (5 mg/kg intravenously [iv] twice daily)
Study: 15073671
Drug: Half-dose ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Half-dose ganciclovir (5 mg/kg iv once daily) plus half-dose foscarnet (90 mg/kg iv once daily)
Study: 9669786
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (n = 586)
Study: 9669786
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (n = 582)
Study: 17427
Drug: Pancuronium 0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 0.08 mg/kg
Study: 2899988
Drug: Vecuronium 0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.08 mg/kg
Study: 3242978
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of histamine and PGD2
Study: 21681697
Drug: Intralesional 5-Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional 5-Fluorouracil combined with topical silicone
Study: 21681697
Drug: Perilesional surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perilesional surgical excision of keloids combined with topical silicone
Study: 18505169
Drug: CD4+ T-cell
Normalized name: Autologous CD4+CD25hiFoxP3+regulatory T cells
DrugBank: Autologous CD4+CD25hiFoxP3+regulatory T cells (DB18655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD4+ T-cell count-guided use of ART (Drug Conservation arm; DC)
Study: 16783561
Drug: Clarithromycin 800
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin 800 mg daily for 6 days
Study: 16783561
Drug: Verapamil 240
Normalized name: verapamil 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 240 mg daily for 6 days
Study: 14666027
Drug: N-acetylcysteine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (100 mg/kg into cardiopulmonary bypass prime followed by infusion at 20 mg.kg(‐1).h(‐1), n = 20)
Study: 10844878
Drug: Orthodox treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodox treatment (Version A)
Study: 10844878
Drug: Unconventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unconventional treatment (Version B)
Study: 1739873
Drug: Calcitonin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin (50 U on alternate days for 2 weeks monthly) + Calcium (500 mg/day)
Study: 1739873
Drug: Calcitonin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin (50 U on alternate days for 2 weeks monthly) + Calcium (500 mg/day) + Phosphate (750 mg/day)
Study: 1739873
Drug: Calcitonin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin (50 U on alternate days for 2 weeks monthly) + Calcium (500 mg/day) + Norandrostenolone decanoate (50 mg/month)
Study: 18565275
Drug: l-tetrahydropalmatine (l-THP)
Normalized name: Tetrahydropalmatine
DrugBank: Tetrahydropalmatine (DB12093)
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-tetrahydropalmatine (l-THP)
Study: 2686340
Drug: Enisoprost (prostaglandin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enisoprost (prostaglandin E1 analogue) at doses of 10, 25, 50, 100, 200, or 400 micrograms
Study: 792865
Drug: Diflucortolone valerate
Normalized name: diflucortolone valerate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflucortolone valerate (ointment)
Study: 22253016
Drug: Oral-sparing group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-sparing group (OR-SP), n = 24
Study: 22253016
Drug: Oral-unsparing group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-unsparing group (OR-USP), n = 24
Study: 22253016
Drug: Oral-sparing group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-sparing group (OR-SP)
Study: 22253016
Drug: Oral-unsparing group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-unsparing group (OR-USP)
Study: 20551644
Drug: FeSO(4) gel
Normalized name: FESO
DrugBank: Fesoterodine (DB06702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FeSO(4) gel (1 mmol/l FeSO(4))
Study: 20551644
Drug: F gel
Normalized name: APF Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: F gel (NaF 1.23%)
Study: 20551644
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (negative control)
Study: 10978853
Drug: HMB supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB supplementation (3.0 g HMB/d)
Study: 30716550
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (home-based EHS plus 10 weekly books)
Study: 30121640
Drug: 5-FU continuous
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU continuous infusion
Study: 24780501
Drug: CER-001 3
Normalized name: CER-001
DrugBank: CER-001 (DB18538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CER-001 3 mg/kg
Study: 24780501
Drug: CER-001 6
Normalized name: CER-001
DrugBank: CER-001 (DB18538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CER-001 6 mg/kg
Study: 24780501
Drug: CER-001 12
Normalized name: CER-001
DrugBank: CER-001 (DB18538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CER-001 12 mg/kg
Study: 22836250
Drug: Hydrocortisone and
Normalized name: hydrocortisone and mydriatics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone and Yohimbine (combined administration)
Study: 20308693
Drug: Caffeine (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (4.5 mg/kg)
Study: 17902094
Drug: High oral
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High oral carbohydrate (CHO) beverage (125 mg/ml)
Study: 17902094
Drug: Low oral
Normalized name: Milkflow oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low oral carbohydrate (CHO) beverage (25 mg/ml)
Study: 16096241
Drug: Vocational training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vocational training programme plus psychosomatic treatment
Study: 11911556
Drug: Sprinkle-dose regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sprinkle-dose regimen of 60-mg MSER capsule on applesauce
Study: 11911556
Drug: Intact 60-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact 60-mg MSER capsule swallowed whole
Study: 26612407
Drug: EAS regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: EAS regimen (esomeprazole 20 mg b.i.d., amoxicillin 500 mg q.i.d., sitafloxacin 100 mg b.i.d.)
Study: 26612407
Drug: EMS regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMS regimen (esomeprazole 20 mg b.i.d., metronidazole 250 mg b.i.d., sitafloxacin 100 mg b.i.d.)
Study: 23550916
Drug: Both adjunctive
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both adjunctive FC therapies
Study: 18412989
Drug: Markers of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Markers of bone turnover (e.g., serum bone alkaline phosphatase, total osteocalcin, procollagen type I N-terminal propeptide)